Humalog 100 units/ml solution for injection in vial

DRUG3 trials

Sponsors

Katholisches Klinikum Bochum gGmbH, Centre Hospitalier Universitaire De Nantes, Oslo Universitetssykehus HF

Conditions

HyperkalemiaNon-toxic acute cardiogenic shockType 1 Diabetes

Phase 1

Influence of various fast-acting mealtime insulin preparations in individuals with type 1 diabetes, with slow, moderate, and rapid gastric emptying, on postprandial blood glucose and the formation of reactive oxygen species

RecruitingCTIS2023-509217-37-00

Katholisches Klinikum Bochum gGmbHType 1 Diabetes

Start: 2024-06-25Target: 20Updated: 2025-09-17

Phase 2

High-dose Insulin Euglycemic Therapy in Non-Toxic Acute Cardiogenic Shock.

Not yet recruitingCTIS2025-523858-13-01

Oslo Universitetssykehus HFNon-toxic acute cardiogenic shock

Target: 20Updated: 2026-07-01

Phase 4

InSaKa trial: Insulin dextrose infusion versus nebulized salbutamol versus combination of salbutamol and insulin dextrose in acute hyperkalemia: a randomized clinical trial

CompletedCTIS2024-514889-40-00

Centre Hospitalier Universitaire De NantesHyperkalemia

Start: 2019-12-20End: 2025-12-20Target: 525Updated: 2024-07-19